MX2024007767A - Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o. - Google Patents
Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o.Info
- Publication number
- MX2024007767A MX2024007767A MX2024007767A MX2024007767A MX2024007767A MX 2024007767 A MX2024007767 A MX 2024007767A MX 2024007767 A MX2024007767 A MX 2024007767A MX 2024007767 A MX2024007767 A MX 2024007767A MX 2024007767 A MX2024007767 A MX 2024007767A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- treatment
- combination
- receptor antagonist
- antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21216889 | 2021-12-22 | ||
| PCT/EP2022/086928 WO2023118098A1 (en) | 2021-12-22 | 2022-12-20 | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007767A true MX2024007767A (es) | 2024-07-04 |
Family
ID=79021054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007767A MX2024007767A (es) | 2021-12-22 | 2022-12-20 | Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250057828A1 (https=) |
| EP (1) | EP4452245A1 (https=) |
| JP (1) | JP2025500346A (https=) |
| KR (1) | KR20240127392A (https=) |
| CN (1) | CN118434414A (https=) |
| AU (1) | AU2022422053A1 (https=) |
| CA (1) | CA3259602A1 (https=) |
| IL (1) | IL313654A (https=) |
| MX (1) | MX2024007767A (https=) |
| TW (1) | TW202342011A (https=) |
| WO (1) | WO2023118098A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| HRP20041026A2 (en) | 2002-04-03 | 2005-06-30 | Orion Corporation | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2017031319A1 (en) | 2015-08-18 | 2017-02-23 | Massachusetts Institute Of Technology | Noradrenergic drug treatment of obstructive sleep apnea |
| GEAP202416602A (en) | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| KR102874891B1 (ko) | 2018-01-30 | 2025-10-21 | 애프니메드, 인코포레이티드 (델라웨어) | 수면 무호흡증을 치료하기 위한 방법 및 조성물 |
| US20210338662A1 (en) * | 2018-09-25 | 2021-11-04 | Bayer Aktiengeselischaft | Alpha-2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| TW202108139A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α２—腎上腺素受體亞型Ｃ（α—２Ｃ）拮抗劑與ＴＡＳＫ１／３通道阻斷劑之組合 |
| EP3965763A1 (en) * | 2019-05-09 | 2022-03-16 | Bayer Aktiengesellschaft | Arylquinoziline derivatives as alpha2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea |
| PE20221025A1 (es) | 2019-11-06 | 2022-06-16 | Bayer Ag | Inhibidores de los receptores a2c adrenergicos |
| WO2022008426A1 (en) * | 2020-07-06 | 2022-01-13 | Bayer Aktiengesellschaft | Combination of an alpha2-adrenoceptor subtype c (alpha-2c) antagonist with a task1/3 channel blocker for the treatment of sleep apnea |
-
2022
- 2022-12-20 CA CA3259602A patent/CA3259602A1/en active Pending
- 2022-12-20 WO PCT/EP2022/086928 patent/WO2023118098A1/en not_active Ceased
- 2022-12-20 MX MX2024007767A patent/MX2024007767A/es unknown
- 2022-12-20 US US18/722,233 patent/US20250057828A1/en active Pending
- 2022-12-20 KR KR1020247024052A patent/KR20240127392A/ko active Pending
- 2022-12-20 JP JP2024537380A patent/JP2025500346A/ja active Pending
- 2022-12-20 IL IL313654A patent/IL313654A/en unknown
- 2022-12-20 TW TW111148913A patent/TW202342011A/zh unknown
- 2022-12-20 EP EP22840695.5A patent/EP4452245A1/en active Pending
- 2022-12-20 AU AU2022422053A patent/AU2022422053A1/en active Pending
- 2022-12-20 CN CN202280085160.3A patent/CN118434414A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240127392A (ko) | 2024-08-22 |
| CA3259602A1 (en) | 2023-06-29 |
| CN118434414A (zh) | 2024-08-02 |
| WO2023118098A1 (en) | 2023-06-29 |
| TW202342011A (zh) | 2023-11-01 |
| IL313654A (en) | 2024-08-01 |
| AU2022422053A1 (en) | 2024-07-11 |
| US20250057828A1 (en) | 2025-02-20 |
| EP4452245A1 (en) | 2024-10-30 |
| JP2025500346A (ja) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000274A (es) | Métodos y composiciones para el tratamiento de apnea del sueño | |
| GEP20227366B (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| DOP2018000142A (es) | Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño | |
| CR10342A (es) | INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3 | |
| CL2011003097A1 (es) | Compuestos derivados fluorados de amino-triazol, agonistas del receptor alx; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias, enfermedades obstructivas de las vias respiratorias, trastornos cardiovasculares y otras. | |
| CL2021000707A1 (es) | Antagonistas del receptor adrenérgico a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño | |
| ECSP22035103A (es) | Inhibidores de los receptores a2c adrenérgicos | |
| MX2025004365A (es) | Metodos y composiciones para el tratamiento de la apnea del sue?o | |
| CU20190060A7 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 útiles en el tratamiento de trastornos respiratorios | |
| CY1115973T1 (el) | Συνδυασμος ινσουλινης με παραγωγα τριαζινης και χρηση αυτου για θεραπεια διαβητη | |
| CL2023000023A1 (es) | Combinación de antagonistas del receptor adrenérgico a2 subtipo c (alfa 2c) con un bloqueador de canales task1/3 para el tratamiento de la apnea del sueño | |
| MX2024007767A (es) | Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o. | |
| IL206615A (en) | The History of Pipridine Sulfonamide, the Process for Preparing it, Medicines Containing It, and Their Use in the Preparation of Medication for Treatment | |
| EA202191480A1 (ru) | Способ получения фармацевтических лекарственных форм, содержащих ингибиторы task-1- и task-3-каналов, и их применение для терапии нарушений дыхания | |
| Kim et al. | Drug Induced Sleep Endoscopy for Poor-Responder to Uvulopalatopharyngoplasty in Patient with Obstructive Sleep Apnea Patients. | |
| MX2024007884A (es) | Combinación de un bloqueador del canal task1/3 con un antagonista del receptor p2x3 para el tratamiento de la apnea del sueño. | |
| MX2024007768A (es) | Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o. | |
| CL2021001315A1 (es) | Antagonistas de los adrenoreceptores a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño | |
| MX2024008522A (es) | Derivados de 2,3-dihidrobenzo[b][1,4]dioxin-2-ilmetil)piperazin-1- ilo para el tratamiento de la apnea del sue?o. | |
| MX2024008523A (es) | Antagonistas del adrenoceptor a2 subtipo c para el tratamiento de la apnea del sue?o. | |
| EA201992569A1 (ru) | Способы и композиции для лечения апноэ во сне | |
| EA201991540A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания | |
| EA201990341A1 (ru) | Замещенные диазагетеробициклические соединения и их применение |